|
|
|
|
|
|
by pilotneko
1674 days ago
|
|
|
Well, that’s the thing, you can’t make a generic version of these drugs because you can’t fully characterize the structure. They are just way too big and complicated, which is scary because a single difference in a glycosolation site can induce an extreme immunogenic response. Best the FDA can do is allow biosimilars and subject them to significantly more testing, which increases the cost 100x (compared to a traditional generic). https://www.pfizer.com/sites/default/files/investors/financi... |
|
|